Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
Open Access
- 5 May 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-12
Abstract
Background: A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associated with a significant improvement in progression-free survival and a trend to an overall survival benefit, supporting progression to phase III randomized trials. Methods: Two hundred and ninety-seven patients will be randomized in a 1:2 ratio between the control arm (consisting of standard of care [SOC] palliative-intent treatments), and the SABR arm (consisting of SOC treatment + SABR to all sites of known disease). Randomization will be stratified by two factors: histology (prostate, breast, or renal vs. all others), and disease-free interval (defined as time from diagnosis of primary tumor until first detection of the metastases being treated on this trial; divided as ≤2 vs. > 2 years). The primary endpoint is overall survival, and secondary endpoints include progression-free survival, cost effectiveness, time to development of new metastatic lesions, quality of life (QoL), and toxicity. Translational endpoints include assessment of circulating tumor cells, cell-free DNA, and tumor tissue as prognostic and predictive markers, including assessment of immunological predictors of response and long-term survival. Discussion: This study will provide an assessment of the impact of SABR on survival, QoL, and cost effectiveness to determine if long-term survival can be achieved for selected patients with 1–3 oligometastatic lesions. Trial registration: Clinicaltrials.gov identifier: NCT03862911. Date of registration: March 5, 2019,Keywords
Funding Information
- Canadian Institute for Health Research (427096)
- Varian Medical Systems
- BC Cancer Agency
This publication has 10 references indexed in Scilit:
- Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trialBMC Cancer, 2019
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialThe Lancet, 2019
- Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysisPLOS ONE, 2018
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid BiopsyCancer Discovery, 2016
- The oligometastatic state—separating truth from wishful thinkingNature Reviews Clinical Oncology, 2014
- International Spine Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic RadiosurgeryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trialBMC Cancer, 2012
- Lung metastasectomy in colorectal cancer: Is this surgery effective in prolonging life?Respirology, 2010
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997
- Oligometastases.Journal of Clinical Oncology, 1995